Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in Patients With Moderate to Severe Ulcerative Colitis
NCT05486104Phase 2Active, not recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Nov 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mufemilast in ulcerative colitis (UC), sponsored by Hemay Pharmaceutical Technology. Started Nov 2022; status: active, not recruiting.
02
Drugs
mufemilast
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05486104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486104.